Our Platform

Our Active Immunotherapy Medicine (AIM) platform is designed to harness the immune system to convert the body into its own natural “drug factory” stimulating the production of antibodies.

AIM technology uses synthetic peptides to mimic and optimally combine biological epitopes to selectively activate the immune system and overcome “immune tolerance”, or the body’s tendency to avoid attacking self-molecules. Conventional vaccine technologies have to date fallen short in attempts to achieve this due to insufficient responses and side effects.

The AIM platform has been scientifically validated, with billions of doses commercialized in animal health, and 10 human clinical trials successfully completed or ongoing.

How it works

The AIM platform works like a sheep in wolf’s clothing, using a synthetic piece of a harmful self-protein that your body normally sees as a “sheep”, linked to a synthetic peptide that acts as “wolf’s clothing,” signaling the immune system that the “sheep” is actually harmful.

The AIM Platform AIM Platform

We take our proprietary platform to address diseases with validated and novel targets.


Break immune tolerance with high response rate and antibody titers

Minimize off-target response

Long acting response

Synthetic, low-cost, scalable

Plug & play, modular

Why does it matter?

The current chronic disease medicine landscape is dominated by monoclonal antibodies (mAbs) which are developed, produced and purified outside the body and then transfused into the patient on a regular basis, as often as bi-weekly. This makes mAbs inherently less efficient than active immunotherapies, which instead stimulate antibody production by the patient’s own immune system, requiring less active material and less frequent treatments.

Our AIMs, on the other hand, are designed to be less than 1% of the COGS of a mAb and more convenient in administration. Our product candidates are designed to be administered in quarterly or longer intervals. The manufacturing processes are highly scalable, require lower capital expenditures and can leverage existing infrastructure to deliver across the globe.

By turning the body into its own antibody “drug factory”, we develop medicines that are easier to make, easier to take and dramatically less costly than mAbs.

Diseases don’t discriminate, and neither should medicines.